Corxel raises $287m as obesity continues to spark investor interest
Corxel’s lead candidate, CX11, is currently in a Phase II trial in the US and a Phase III trial in China.
Therapy Area
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
J&J’s Caplyta doubles remission rate in MDD patients
JPM26: Enanta outlines strategy to lead in RSV therapeutics
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition
Drugmakers welcome FDA’s GLP-1RA suicide warning removal request
JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions
JPM26: Pfizer’s Metsera deal supercharges its obesity strategy
